In vitro activity of ceftaroline against Staphylococcus aureus isolated in 2012 from Asia-Pacific countries as part of the AWARE surveillance program

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 1, 2016, Pages 343-347

  Biedenbach, Douglas J ^a   Alm, Richard A ^b,c   Lahiri, Sushmita D ^b,c   Reiszner, Edina ^b   Hoban, Daryl J ^a   Sahm, Daniel F ^a   Bouchillon, Samuel K ^a   Ambler, Jane E ^b,d  

^a International Health Management Associates   (United States)

^b ASTRAZENECA   (United Kingdom)

^c Macrolide Pharmaceuticals   (United States)

^d CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; CEFTAROLINE FOSAMIL; CLINDAMYCIN; DAPTOMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN BINDING PROTEIN 2A; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CEPHALOSPORIN DERIVATIVE; MECA PROTEIN, STAPHYLOCOCCUS AUREUS; PENICILLIN BINDING PROTEIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BROTH DILUTION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MIC50; MIC90; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; AMINO ACID SUBSTITUTION; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; GENE EXPRESSION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR EPIDEMIOLOGY; MULTILOCUS SEQUENCE TYPING; SOUTHEAST ASIA; STAPHYLOCOCCAL INFECTIONS;

AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; ASIA, SOUTHEASTERN; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; CEPHALOSPORINS; EPIDEMIOLOGICAL MONITORING; GENE EXPRESSION; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; MULTILOCUS SEQUENCE TYPING; PENICILLIN-BINDING PROTEINS; STAPHYLOCOCCAL INFECTIONS;

EID: 84957885704     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01867-15     Document Type: Article

References (38)

1. Chen CJ, Huang YC. 2014. New epidemiology of Staphylococcus aureus infection in Asia. Clin Microbiol Infect 20:605-623. http://dx.doi.org/10.1111/1469-0691.12705.
2. Su CH, Chang SC, Yan JJ, Tseng SH, Chien LJ, Fang CT. 2013. Excess mortality and long-term disability from healthcare-associated Staphylococcus aureus infections: a population-based matched cohort study. PLoS One 8:e71055. http://dx.doi.org/10.1371/journal.pone.0071055.
3. Kollipara R, Downing C, Lee M, Guidry J, Curis S, Tyring S. 2014. Current and emerging drugs for acute bacterial skin and skin structure infections: an update. Expert Opin Emerg Drugs 19:431-440. http://dx.doi.org/10.1517/14728214.2014.955015.
4. Gould IM, David MZ, Esposito S, Garau J, Lina G, Mazzei T, Peters G. 2012. New insights into methicillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents 39:96-104. http://dx.doi.org/10.1016/j.ijantimicag.2011.09.028.
5. Rincon S, Panesso D, Diaz L, Carvajal LP, Reyes J, Munita JM, Arias CA. 2014. Resistance to "last resort" antibiotics in Gram-positive cocci: the post-vancomycin era. Biomedica 34(Suppl 1):191-208. http://dx.doi.org/10.7705/biomedica.v34i0.2210.
6. Rodvold KA, McConeghy KW. 2014. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clin Infect Dis 58(Suppl 1):S20-S27. http://dx.doi.org/10.1093/cid/cit614.
7. Casapao AM, Steed ME, Levine DP, Rybak MJ. 2012. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. Expert Opin Pharmacother 13:1177-1186. http://dx.doi.org/10.1517/14656566.2012.685718.
8. Shirley DT, Heil EL, Johnson JK. 2013. Ceftaroline fosamil: a brief clinical review. Infect Dis Ther 2:95-110. http://dx.doi.org/10.1007/s40121-013-0010-x.
9. Forest Laboratories.2012. Teflaro™ (ceftaroline fosamil) prescribing information (10/2012). Forest Laboratories, New York, NY. http://www.frx.com/pi/teflaro-pi.pdf.
10. Electronic Medicines Compendium. Zinforo 600 mg powder for concentration for solution for infusion. Summary of product characteristics. Datapharm Communications, Leatherhead, Surrey, United Kingdom. http://www.medicines.org.uk/emc/searchresults.aspx?term=Zinforo&searchtype=QuickSearch.
11. Arshad S, Hartman P, Zervos MJ. 2014. A novel treatment option for MRSA pneumonia: ceftaroline fosamil-yielding new hope in the fight against a persistent infection. Expert Rev Anti Infect Ther 12:727-729. http://dx.doi.org/10.1586/14787210.2014.908118.
12. Bally M, Dendukuri N, Sinclair A, Ahern SP, Poisson M, Brophy J. 2012. A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven methicillin-resistant Staphylococcus aureus infection. Int J Antimicrob Agents 40:479-495. http://dx.doi.org/10.1016/j.ijantimicag.2012.08.004.
13. Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Kaye KS, Mynatt RP, Molloy LM, Pogue JM, Rybak MJ. 2014. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother 58:2541-2546. http://dx.doi.org/10.1128/AAC.02371-13.
14. Critchley IA, Eckburg PB, Jandourek A, Biek D, Friedland HD, Thye DA. 2011. Review of ceftaroline fosamil microbiology: integrated FOCUS studies. J Antimicrob Chemother 66(Suppl 3):iii45-iii51. http://dx.doi.org/10.1093/jac/dkr098.
15. File TM, Jr, Wilcox MH, Stein GE. 2012. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis 55(Suppl 3):S173-S180. http://dx.doi.org/10.1093/cid/cis559.
16. Frampton JE. 2013. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia. Drugs 73:1067-1094. http://dx.doi.org/10.1007/s40265-013-0075-6.
17. Goodman JJ, Martin SI. 2012. Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections. Ther Clin Risk Manag 8:149-156. http://dx.doi.org/10.2147/TCRM.S17413.
18. Lodise TP, Low DE. 2012. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Drugs 72:1473-1493. http://dx.doi.org/10.2165/11635660-000000000-00000.
19. Pasquale TR, Tan MJ, Trienski TL, File TM, Jr. 2015. Methicillin-resistant Staphylococcus aureus nosocomial pneumonia patients treated with ceftaroline: retrospective case series of 10 patients. J Chemother 27:29-34. http://dx.doi.org/10.1179/1973947813Y.0000000156.
20. Santos PD, Davis A, Jandourek A, Smith A, David Friedland H. 2013. Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience. J Chemother 25:341-346. http://dx.doi.org/10.1179/1973947813Y.0000000144.
21. Long SW, Olsen RJ, Mehta SC, Palzkill TG, Cernoch PL, Perez KK, Musick WL, Rosato AE, Musser JM. 2014. PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 58:6668-6674. http://dx.doi.org/10.1128/AAC.03622-14.
22. Chan LC, Basuino L, Diep B, Hamilton S, Chatterjee SS, Chambers HF. 2015. Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 59:2960-2963. http://dx.doi.org/10.1128/AAC.05004-14.
23. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craif AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK, Active Bacterial Core surveillance (ABCs) MRSA Investigators. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771. http://dx.doi.org/10.1001/jama.298.15.1763.
24. Ray GT, Suaya JA, Baxter R. 2012. Trends and characteristic of culture-confirmed Staphylococcus aureus infections in a large U.S. integrated health care organization. J Clin Microbiol 50:1950-1957. http://dx.doi.org/10.1128/JCM.00134-12.
25. Rubinstein E, Kollef MH, Nathwani D. 2008. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 46(Suppl 5):S378-S385. http://dx.doi.org/10.1086/533594.
26. Woods C, Colice G. 2014. Methicillin-resistant Staphylococcus aureus pneumonia in adults. Expert Rev Respir Med 8:641-651. http://dx.doi.org/10.1586/17476348.2014.940323.
27. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards, 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
28. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
29. Alm RA, McLaughlin RE, Kos VN, Sader HS, Iaconis JP, Lahiri SD. 2014. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. J Antimicrob Chemother 69:2065-2075. http://dx.doi.org/10.1093/jac/dku114.
30. Sader HS, Flamm RK, Jones RN. 2013. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). Diagn Microbiol Infect Dis 76:61-68. http://dx.doi.org/10.1016/j.diagmicrobio.2013.01.005.
31. Flamm RK, Sader HS, Jones RN. 2014. Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011). Braz J Infect Dis 18:187-195. http://dx.doi.org/10.1016/j.bjid.2013.11.005.
32. Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN. 2012. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Clin Infect Dis 55:S206-214. http://dx.doi.org/10.1093/cid/cis563.
33. Flamm RK, Sader HS, Jones RN. 2014. Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE program, 2009-2011. Diagn Microbiol Infect Dis 78:437-442. http://dx.doi.org/10.1016/j.diagmicrobio.2013.10.020.
34. Flamm RK, Sader HS, Farrell DJ, Jones RN. 2012. Ceftaroline potency among 9 US census regions: report from the 2010 AWARE program. Clin Infect Dis 55(Suppl 3):S194-S205. http://dx.doi.org/10.1093/cid/cis562.
35. Castanheira M, Jones RN, Sader HS. 2014. Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel. J Chemother 26:202-210. http://dx.doi.org/10.1179/1973947813Y.0000000135.
36. Kelley WL, Jousselin A, Barras C, Lelong E, Renzoni A. 2015. Missense mutations in PBP2A affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in western Switzerland archived since 1998. Antimicrob Agents Chemother 59:1922-1930. http://dx.doi.org/10.1128/AAC.04068-14.
37. Mendes RE, Tsakris A, Sader HS, Jones RN. 2012. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J Antimicrob Chemother 67:1321-1324. http://dx.doi.org/10.1093/jac/dks069.
38. Lahiri SD, McLaughlin RE, Whiteaker JD, Ambler JE, Alm RA. 2015. Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline. J Antimicrob Chemother 70:2488-2498. http://dx.doi.org/10.1093/jac/dkv131.